What are the pharmacokinetic characteristics of alprazolam?

Pharmacokinetics of Alprazolam

Alprazolam is rapidly absorbed with peak plasma concentrations at 1-2 hours, has an elimination half-life of approximately 11.2 hours (range 6.3-26.9 hours) in healthy adults, is 80% protein-bound, and is extensively metabolized via CYP3A4 to minimally active metabolites that contribute little to clinical effects 1.

Absorption

Alprazolam is readily absorbed following oral administration with excellent bioavailability:

• Bioavailability: 80-100% after oral dosing 1
• Time to peak concentration (Tmax): 1-2 hours for immediate-release formulations 1, 2
• Peak plasma levels: Dose-proportional, ranging from 8.0-37 ng/mL over doses of 0.5-3.0 mg 1
• Dose linearity: Pharmacokinetics are dose-independent and remain unchanged during multiple-dose treatment 3

The immediate-release formulation shows rapid onset, with IV administration producing sedation within approximately 0.48 hours, while oral formulations show slightly delayed but comparable effects 2.

Distribution

• Volume of distribution: 0.8-1.3 L/kg (or 0.72-0.84 L/kg in some studies) 1, 3, 2
• Protein binding: 80% bound to human serum protein, primarily serum albumin 1
• CNS penetration: Alprazolam crosses the blood-brain barrier readily due to its lipid solubility 4
• Transplacental passage: Assumed to occur based on similarity to other benzodiazepines 1
• Breast milk excretion: Assumed to be excreted in human milk 1

Metabolism

Alprazolam is extensively metabolized primarily via hepatic CYP3A4 1:

• Primary metabolites:

  • 4-hydroxyalprazolam
  • α-hydroxyalprazolam
  • Benzophenone derivative (essentially inactive)

• Metabolite activity: Both hydroxylated metabolites have significantly lower potency (relative potencies of 0.20 and 0.66 respectively) and appear at plasma concentrations less than 4% of parent drug, contributing minimally to pharmacological effects 1, 3

• Metabolite concentrations: Combined plasma concentrations of metabolites remain less than 15% of unchanged alprazolam across all doses 5

Elimination

• Elimination half-life:

  • Healthy adults: 11.2 hours (range 6.3-26.9 hours) 1, 3
  • No significant difference between IV and oral routes 2

• Clearance: 0.7-1.5 mL/min/kg (or 0.74-0.89 mL/min/kg) 1, 3, 2

• Route of excretion: Primarily renal, with alprazolam and metabolites excreted in urine 1

• Steady-state considerations: Mean steady-state plasma concentrations change by 10-12 mcg/L for each 1 mg/day dosage change 3

Special Populations

Elderly Patients

• Half-life: Increased to 16.3 hours (range 9.0-26.9 hours) compared to 11.0 hours in younger adults 1
• Plasma concentrations: 15% higher maximal concentrations due to reduced clearance 1
• Clinical implication: Higher sensitivity to benzodiazepine effects; smallest effective doses should be used to prevent ataxia and oversedation 1

Hepatic Impairment

• Alcoholic liver disease: Half-life ranges from 5.8-65.3 hours (mean 19.7 hours) versus 6.3-26.9 hours (mean 11.4 hours) in healthy subjects 1
• Clearance: Significantly reduced in cirrhosis 3

Renal Impairment

• Lorazepam comparison: While lorazepam shows increased half-life and duration in renal failure 6, alprazolam shows variable effects
• CAPD patients: Higher free fraction, lower apparent oral clearance, and lower free clearance compared to healthy subjects or hemodialysis patients 7
• Hemodialysis patients: Similar pharmacokinetics to normal subjects except for higher free fraction 7
• Protein binding: Reduced in renal disease, resulting in increased free fraction 3, 7

Obesity

• Half-life: Prolonged to 9.9-40.4 hours (mean 21.8 hours) versus 6.3-15.8 hours (mean 10.6 hours) in non-obese subjects 1

Race

• Asian populations: Approximately 15% higher maximal concentrations and 25% longer half-life compared to Caucasians 1

Gender and Other Factors

• Gender: No effect on pharmacokinetics 1, 3
• Menstrual cycle: No influence on pharmacokinetics 3
• Cigarette smoking: May reduce concentrations by up to 50% compared to non-smokers 1

Drug Interactions

CYP3A4 Inhibitors (Increase Alprazolam Exposure)

Strong inhibitors are contraindicated or require extreme caution 1:

• Ketoconazole: 3.98-fold increase in AUC
• Itraconazole: 2.70-fold increase
• Nefazodone: 1.98-fold increase
• Fluvoxamine: 1.96-fold increase
• Erythromycin: 1.61-fold increase
• Fluoxetine: 46% increase in Cmax, 21% decrease in clearance, 17% increase in half-life 1
• Propoxyphene: 38% decrease in clearance, 58% increase in half-life 1
• Oral contraceptives: 18% increase in Cmax, 22% decrease in clearance, 29% increase in half-life 1

CYP3A4 Inducers (Decrease Alprazolam Exposure)

• Carbamazepine: Increases oral clearance from 0.90 to 2.13 mL/min/kg and shortens half-life from 17.1 to 7.7 hours 1

No Significant Interactions

• Propranolol, metronidazole, disulfiram, ethanol 3
• Digoxin (alprazolam does not alter digoxin pharmacokinetics) 3
• Warfarin (no effect on prothrombin or plasma warfarin levels) 1

Alprazolam Effects on Other Drugs

• Imipramine and desipramine: Steady-state concentrations increased by 31% and 20% respectively with alprazolam doses up to 4 mg/day 1

Clinical Pharmacodynamics

Concentration-Effect Relationships

• Therapeutic range: Some evidence suggests optimal anxiety reduction in panic disorder occurs at steady-state concentrations of 20-40 mcg/L, with higher concentrations potentially needed for panic attack suppression 3

• Brain concentrations: After single doses, peak unbound interstitial brain concentrations range from 4-33 nM (0.25-2 mg immediate-release) and 3-54 nM (0.5-10 mg extended-release) 4

• Hysteresis: Sustained-release formulations exhibit clockwise hysteresis loops (effect lags concentration), contrasting with counterclockwise loops seen with immediate-release formulations, suggesting distribution-related delays rather than metabolite activity 5

Critical Clinical Considerations

The pharmacokinetic profile of alprazolam differs importantly from other benzodiazepines used in critical care settings 6. While midazolam and lorazepam are discussed extensively in ICU sedation guidelines, alprazolam is not recommended for ICU sedation due to:

• Intermediate onset compared to midazolam's rapid onset
• Longer duration than desired for titratability in acute settings
• Lack of parenteral formulation suitable for continuous infusion
• Strong association with delirium development (benzodiazepines are among the strongest independent risk factors for ICU delirium) 8

Dependence and withdrawal risk: The pharmacokinetic properties—particularly the relatively short half-life combined with high potency and rapid CNS penetration—contribute to significant abuse and dependence liability 9, 10. Doses exceeding 4 mg/day are associated with increased difficulty tapering and more severe withdrawal reactions, including potentially life-threatening seizures 1.